THE NEXT BIG LIVER DISEASE
NASH: Huge potential market, tough clinical development
By Brian Orelli
Monday, March 31, 2014
With hepatitis C treatments largely figured out, biotechs and investors have turned to the newest liver disease without a treatment: nonalcoholic steatohepatitis (NASH).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.